HCC1954
Rincon Bio performs HCC1954 xenograft models to test efficacy of preclinical therapies. Please see below for additional information or to request a quote.
Breast
HCC1954 was derived from a primary stage IIA, grade 3 invasive ductal carcinoma with no lymph node metastases.
The HCC1954 is a poorly differentiated cell line initiated on October 30, 1995; it took about 4 months to establish. Ref
Notes
HCC1954 is positive for the epithelial cell specific marker Epithelial Glycoprotein 2 and for cytokeratin 19, and is negative for expression of estrogen receptor (ER) and progesterone receptor (PR).
Her2/neu is overexpressed in the ELISA assay. Ref
in vivo
Forms tumors in nude mice
Used in xenografts to test the efficacy of novel cancer therapeutics
Request Quote
Receive a quote within one business day for an HCC1954 xenograft
Rincon Bio Growth Curves
Cell Line: HCC1954
Mouse Strain: Nude from Envigo
Gender: Female
Positive Control: Kadcyla
Concentration: 0.1, 0.33, 0.5, 1, 3.3, 5.5mg/kg
Matrigel: Yes
Dosing: Tail Vein, 1 time
From implant to stratification: 27 days
Cells Implanted per Animal: 5 million
Cell Line: HCC1954
Mouse Strain: Nude from Envigo
Gender: Female
Positive Control: Kadcyla
Concentration: 2.5, 5 kg/mg
Matrigel: Yes
Dosing: Tail Vein, 1 time
From implant to stratification: 24 days
Cells Implanted per Animal: 5 million
WHY WORK WITH
RINCON BIO?
DOMESTIC QUALITY at COMPETITIVE PRICES
When you work with Rincon Bio, rest assured that all cancer efficacy studies will be performed in the USA, at competitive prices
PERSONAL TOUCH
We love our clients! We are easy to work with. And we take a personal interest in our clients and their studies.